Protocol Number: 03-I-0310

Title:

Immune Response to Influenza Vaccination in HIV-Infected Individuals

Number:

03-I-0310

Summary:

This study will evaluate how HIV infection, including CD4 cell count and viral load, affects the patient's ability to produce antibodies in response to vaccination with the influenza (flu) vaccine. Earlier studies have shown that people with HIV infection do not respond as well as healthy subjects to flu vaccine; that is, they don't make as many antibodies in response to the vaccine. Before the use of current anti-HIV medications, antibodies made to flu vaccination in HIV-positive individuals was related to their CD4 cell count. This trial will examine how CD4 counts and the amount of virus in the blood affect how much and what kind of antibodies the body makes to the flu vaccine.

HIV-infected patients and healthy normal volunteers between 18 and 60 years of age may be eligible for this study. Healthy subjects will serve as controls to make sure the flu vaccine works (i.e., stimulates production of enough antibody to protect against the flu), and to compare the amount of antibodies made by HIV-positive and HIV-negative people. Candidates will be screened with a medical history and blood tests (see below). Women who are able to have children will have a pregnancy test. Pregnant women are excluded from the study.

Participants will undergo the following procedures:

1) Blood drawing for the following tests:

- Routine tests (complete blood count, kidney and liver functions, electrolyte levels).

- CD4 cell count.

- HLA typing (a genetic marker of the immune system) if it has not already been done at the NIH. This test may be used to try to identify factors associated with the rate of progression of HIV disease or related conditions. Determining HLA type is necessary to be able to perform certain research studies. Some HLA types have been associated with an increased risk of certain diseases like arthritis and other rheumatologic problems.

- Viral load (HIV-infected patients only).

- Influenza antibody levels.

- B cell levels.

2) Flu vaccination

3) Follow-up visits on days, 7, 28, and 54 after vaccination for the following:

- Review of any illnesses or fever.

- Review of medications, if any changes were made.

- Repeat blood tests.

Sponsoring Institute:

National Institute of Allergy and Infectious Diseases (NIAID)

Recruitment Detail

Type: Active Accrual Of New Subjects

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria:

INCLUSION CRITERIA:

HIV Positive:

1. Age greater than or equal 18 but less than or equal to 60 years old and willing and able to give informed consent

2. Enrollment during the USA influenza season (October-March)

3. Self-reported history of HIV infection at enrollment (If NIH HIV testing does not confirm that the subject is HIV-positive, the subject will be discontinued from the study and not included in the analysis.)

HIV Negative:

1. Age greater than or equal to 18 but less than or equal to 60 years old and willing and able to give informed consent

2. Enrollment during USA influenza season (October-March)

3. Self-reported healthy HIV-negative (If NIH HIV testing does not confirm that the subject is HIV-negative, the subject will be discontinued from the study and not included in the analysis.)

EXCLUSION CRITERIA:

HIV Positive:

1. Self-reported history of vaccination with the trivalent influenza preparation used for the current influenza season

2. Self-reported vaccination with any vaccine within the one month period prior to study enrollment

3. Acute febrile illness (may defer vaccine until resolved)

4. History of hypersensitivity to any influenza vaccine components including thimerosal or egg

5. History of Guillain-Barre syndrome

6. Intention to receive any other vaccine during the study period

7. Pregnancy

8.Self-reported treatment with immunomodulator/immunosuppressive drugs (interleukins, corticosteroids, or G(M)-CSF in the 4 weeks prior to enrollment

9. Self-reported history of IL-2 administration within the past 5 years

10. Use of theophylline preparations or warfarin because of the theoretical possibilities, of enhanced drug effects and toxicities post influenza vaccination

11. Active infection or other serious illness other than HIV that might affect the immune response to a vaccine

12. Current alcohol, substance abuse, or systemic/psychiatric illness that potentially could interfere with patient compliance and ability to make study visits

HIV Negative:

1. Self-reported history of vaccination with the trivalent influenza preparation used for the current influenza season

2. Self-reported vaccination with any vaccine within the one month period prior to study enrollment

3. Acute febrile illness (may defer vaccine until resolved)

4. History of hypersensitivity to any influenza vaccine components including thimerosal or egg

5. History of Guillain-Barre syndrome

6. Intention to receive any other vaccine during the study period

7. Pregnancy

8. Self-reported treatment with immunomodulator/immunosuppressive drugs (interleukins, corticosteroids, or G(M)-CSF in the 4 weeks prior to enrollment

9. Use of theophylline preparations or warfarin because of the theoretical possibilities, of enhanced drug effects and toxicities post influenza vaccination

10. Any medical conditions, or medication use might affect the immune response to a vaccine

11. Current alcohol, substance abuse, or systemic/psychiatric illness that potentially could interfere with patient compliance and ability to make study visit

Special Instructions: Currently Not Provided

Keywords:

Immunization

Immune Activation

Flu

Antibodies

Titers

Recruitment Keywords:

HIV

Healthy Volunteer

HV

Conditions:

HIV Infections

Investigational Drug(s):

None

Investigational Device(s):

None

Contacts:

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

Electronic Mail:prpl@mail.cc.nih.gov

Citations:

McNeil AC, Shupert WL, Iyasere CA, Hallahan CW, Mican JA, Davey RT Jr, Connors M. High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83. PMID: 11717444

Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donoghue ET, Hallahan CW, Liu S, Ehler LA, Planta MA, Kottilil S, Chun TW, Fauci AS. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6057-62. Epub 2003 May 01. PMID: 12730375

Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000 Jul 1;18(26):3040-9. PMID: 10825608

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/21/2004